

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Next Science Limited
<b>ABN</b>	47 622 382 549

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Harry Thomas Hall, IV (I.V.)
<b>Date of appointment</b>	10 July 2023

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
Nil

+ See chapter 19 for defined terms.

## Appendix 3X

### Initial Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Name of holder & nature of interest	Number & class of Securities
<p>Note: Provide details of the circumstances giving rise to the relevant interest.</p>	<p>Nil</p>

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Executive Services Agreement commencing 10 July 2023
<b>Nature of interest</b>	<p>The Managing Director / CEO is entitled to an initial sign on grant of performance rights equivalent in value to US\$500,000 (based on the 20 trading day VWAP of NXS shares prior to the date of announcement of the CEO's appointment on 16 June 2023), vesting in equal tranches annually over a three-year period subject to continuous employment through to each vesting date.</p> <p>The Company intends to seek shareholder approval for the grant of rights at the 2024 Annual General Meeting (<b>AGM</b>). The rights will be granted following the AGM. If shareholder approval of the grant of rights is not obtained, vested rights will be satisfied with NXS shares purchased on-market.</p>
<b>Name of registered holder (if issued securities)</b>	N/A
<b>No. and class of securities to which interest relates</b>	Performance rights equivalent in value to US\$500,000 as detailed above.

---

+ See chapter 19 for defined terms.